F 1.9 . The homeostasis model assessment for insulin resistance (HOMA-IR) was used to estimate insulin resistance as determined by the following formula: ((fasting insulin (U/mL) ?fasting glucose (mmol/liter))/22.5 [24]. Serum estradiol was measured using an electrochemiluminescence immunoassay analyzer (Roche Modular Analytics E170; Roche, Mannheim, Germany) with a CV of 2.4 . Serum adiponectin l
E 2 cm ESR1-positive and ESR2-low, tumor size >2 cm ESR1-positive or ESR2-low or both, tumor size 2 cm ESR1-positive or ESR2-low or both, tumor size >2 cmaDisease-free survival Number 837 199 638 312 525 410 410 378 459 306 332 175 218 147 181 334 386 HR 95 CI P value 0.001 0.59 0.001 0.19 0.007 0.003 0.43 0.001 0.31 0.001 0.34 0.84 0.005 0.66 0.25 0.82 0.73 0.93 0.94 0.76 1.17 0.79 0.68 0.90 0
Protein DC-SCRIPT. J Leukoc Biol 2006, 79:1083-1091. 5. Triantis V, Trancikova DE, Looman MW, Hartgers FC, Janssen RA, Adema GJ: Identification and characterization of DC-SCRIPT, a novel dendritic cellexpressed member of the zinc finger family of transcriptional regulators. J Immunol 2006, 176:1081-1089. 6. Lopez-Garcia J, Periyasamy M, Thomas RS, Christian M, Leao M, Jat P, Kindle KB, Heery DM, P
Receptor modulation and prognostic significance in primary breast cancer. J Natl Cancer Inst 2010, 102:54-68. 8. Ramadoss P, Marcus C, Perdew GH: Role of the aryl hydrocarbon receptor in drug metabolism. Expert Opin Drug Metab Toxicol 2005, 1:9-21. 9. Osborne CK, Schiff R, Fuqua SA, Shou J: Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001, 7:4338s-434
Ith DFS, MFS, OS, and PFS, respectively. In multivariable analysis, Cox proportional hazards models for DFS, MFS, OS, and PFS were applied to test DCSCRIPT levels added to models with traditional factors. The proportional hazards assumptions were checked with Schoenfeld residuals. The analyses were stratified if necessary. The models for DFS, MFS, and OS for LNN patients who had not received adjuv
Noma in situ; DC-SCRIPT, dendritic cell-specific transcript gene; ERBB2+, HER2neu-positive; ESR, estrogen receptor gene; IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma; PGR, progesterone receptor gene; pT1, small tumor without lymphatic/vascular invasion.(Spearman's rho = 0.87; P
Nd multivariable analysis higher DC-SCRIPT levels were associated with a favorable outcome for both the entire cohort and patients with lymph node-negative (LNN) disease that did not receive adjuvant therapy (DFS, MFS and OS; all, P